nach oben

Clinical Oral Investigations

Erschienen in:

16.06.2018 | Original Article

Topical pimecrolimus versus betamethasone for oral lichen planus: a randomized clinical trial

verfasst von: Ola M. Ezzatt, Iman M. Helmy

Erschienen in: Clinical Oral Investigations | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Objectives

Oral lichen plans (OLP) is a potentially malignant inflammatory mucocutaneous disease. CD133 is an investigated surface marker for cancer stem-like cells (CSCs) that may be involved in tumor initiation in head and neck carcinomas. We compared short-term clinical effectiveness of topical pimecrolimus as selective inflammatory cytokine release inhibitor with betamethasone cream for erosive/atrophic OLP and investigated the influence of this therapy on CD133 expression.

Material and methods

Thirty patients were randomly assigned into two equal groups to receive topical pimecrolimus (group I) or betamethasone (group II) four times daily for 4 weeks. A marker lesion in each patient were assessed at baseline using clinical score (CS) and visual analog scale (VAS) then at 1, 2, and 4 weeks and after 4 weeks of treatment-free period. CD133 expression was detected in pre- and post-treatment immunostained sections.

Results

Both drugs showed a reduction in CS, VAS, and CD133 expressions after treatment termination (p < 0.001). Pimecrolimus-treated lesions showed significant higher 1st week reduction in severity (33.1% (22.2)), pain score (57.53% (14.27)), less recurrence in follow-up period and less CD133 expression by the end of the 1st 4 weeks compared with betamethasone.

Conclusion

Pimecrolimus showed earlier clinical response and less recurrence rate compared with standard topical corticosteroid in symptomatic OLP lesions, and both treatment reduced CD133-positive CSC population.

Clinical relevance

The study proved the benefits of topical pimecrolimus in early management of painful lesions of OLP and its ability to inhibit CSCs, suggesting a possible role in reducing risk of malignant transformation.

Nur mit Berechtigung zugänglich

Lehman JS, Tollefson MM, Gibson LE (2009) Lichen planus. Int J Dermatol 48:682–694. https://doi.org/10.1111/j.1365-4632.2009.04062.xCrossRefPubMed

Silverman S, Gorsky M, Lozada-Nur F, Giannotti K (1991) A prospective study of findings and management in 214 patients with oral lichen planus. Oral Surg Oral Med Oral Pathol 72:665–670CrossRef

Eisen D (2002) The clinical features, malignant potential, and systemic associations of oral lichen planus: a study of 723 patients. J Am Acad Dermatol 46:207–214. https://doi.org/10.1067/mjd.2002.120452CrossRefPubMed

Eisen D, Carrozzo M, Bagan Sebastian J-V, Thongprasom K (2005) Number V oral lichen planus: clinical features and management. Oral Dis 11:338–349. https://doi.org/10.1111/j.1601-0825.2005.01142.xCrossRefPubMed

Sugerman PB, Savage NW, Walsh LJ, Zhao ZZ, Zhou XJ, Khan A, Seymour GJ, Bigby M (2002) The pathogenesis of oral lichen planus. Crit Rev Oral Biol Med 13:350–365. https://doi.org/10.1177/154411130201300405CrossRefPubMed

Roopashree MR, Gondhalekar RV, Shashikanth MC, George J, Thippeswamy SH, Shukla A (2010) Pathogenesis of oral lichen planus—a review. J Oral Pathol Med 39:729–734. https://doi.org/10.1111/j.1600-0714.2010.00946.xCrossRefPubMed

Warnakulasuriya S, Johnson NW, van der Waal I (2007) Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med 36:575–580. https://doi.org/10.1111/j.1600-0714.2007.00582.xCrossRefPubMed

Fitzpatrick SG, Hirsch SA, Gordon SC (2014) The malignant transformation of oral lichen planus and oral lichenoid lesions. J Am Dent Assoc 145:45–56. https://doi.org/10.14219/jada.2013.10CrossRefPubMed

Agha-Hosseini F, Sheykhbahaei N, SadrZadeh-Afshar M-S (2016) Evaluation of potential risk factors that contribute to malignant transformation of oral lichen planus: a literature review. J Contemp Dent Pract 17:692–701CrossRef

10.

Bermejo-Fenoll A, Sanchez-Siles M, López-Jornet P, Camacho-Alonso F, Salazar-Sanchez N (2009) Premalignant nature of oral lichen planus. A retrospective study of 550 oral lichen planus patients from South-Eastern Spain. Oral Oncol 45:e54–e56. https://doi.org/10.1016/j.oraloncology.2009.01.009CrossRefPubMed

11.

Zhang Z, Filho MS, Nör JE (2012) The biology of head and neck cancer stem cells. Oral Oncol 48:1–9CrossRef

12.

Krishnamurthy S, Nor JE (2012) Head and neck Cancer stem cells. J Dent Res 91:334–340. https://doi.org/10.1177/0022034511423393CrossRefPubMedPubMedCentral

13.

Wu Y, Wu PY (2009) CD133 as a marker for cancer stem cells: progresses and concerns. Stem Cells Dev 18:1127–1134. https://doi.org/10.1089/scd.2008.0338CrossRefPubMed

14.

Zhou L, Wei X, Cheng L, Tian J, Jiang JJ (2007) CD133, one of the markers of cancer stem cells in Hep-2 cell line. Laryngoscope 117:455–460. https://doi.org/10.1097/01.mlg.0000251586.15299.35CrossRefPubMed

15.

Ravindran G, Devaraj H (2012) Aberrant expression of CD133 and musashi-1 in preneoplastic and neoplastic human oral squamous epithelium and their correlation with clinicopathological factors. Head Neck 34:1129–1135. https://doi.org/10.1002/hed.21896CrossRefPubMed

16.

Sun L, Feng J, Ma L, Liu W, Zhou Z (2013) CD133 expression in oral lichen planus correlated with the risk for progression to oral squamous cell carcinoma. Ann Diagn Pathol 17:486–489. https://doi.org/10.1016/j.anndiagpath.2013.06.004CrossRefPubMed

17.

Eisen D (2003) The clinical manifestations and treatment of oral lichen planus. Dermatol Clin 21:79–89CrossRef

18.

Ahluwalia A (1998) Topical glucocorticoids and the skin—mechanisms of action: an update. Mediat Inflamm 7:183–193. https://doi.org/10.1080/09629359891126CrossRef

19.

Fisher DA (1995) Adverse effects of topical corticosteroid use. West J Med 162:123–126PubMedPubMedCentral

20.

Grassberger M, Steinhoff M, Schneider D, Luger TA (2004) Pimecrolimus—an anti-inflammatory drug targeting the skin. Exp Dermatol 13:721–730. https://doi.org/10.1111/j.0906-6705.2004.00269.xCrossRefPubMed

21.

Stuetz A, Baumann K, Grassberger M, Wolff K, Meingassner JG (2006) Discovery of topical calcineurin inhibitors and pharmacological profile of pimecrolimus. Int Arch Allergy Immunol 141:199–212CrossRef

22.

Passeron T, Lacour J-P, Fontas E, Ortonne J-P (2007) Treatment of oral erosive lichen planus with 1% pimecrolimus cream: a double-blind, randomized, prospective trial with measurement of pimecrolimus levels in the blood. Arch Dermatol 143:472–476. https://doi.org/10.1001/archderm.143.4.472CrossRefPubMed

23.

Volz T, Caroli U, Lüdtke H, Bräutigam M, Kohler-Späth H, Röcken M, Biedermann T (2008) Pimecrolimus cream 1% in erosive oral lichen planus—a prospective randomized double-blind vehicle-controlled study. Br J Dermatol 159:936–941. https://doi.org/10.1111/j.1365-2133.2008.08726.xCrossRefPubMed

24.

Swift JC, Rees TD, Plemons JM, Hallmon WW, Wright JC (2005) The effectiveness of 1% pimecrolimus cream in the treatment of oral erosive lichen planus. J Periodontol 76:627–635. https://doi.org/10.1902/jop.2005.76.4.627CrossRefPubMed

25.

Gorouhi F, Solhpour A, Beitollahi JM, Afshar S, Davari P, Hashemi P, Nassiri Kashani M, Firooz A (2007) Randomized trial of pimecrolimus cream versus triamcinolone acetonide paste in the treatment of oral lichen planus. J Am Acad Dermatol 57:806–813. https://doi.org/10.1016/j.jaad.2007.06.022CrossRefPubMed

26.

Lodi G, Carrozzo M, Furness S, Thongprasom K (2012) Interventions for treating oral lichen planus: a systematic review. Br J Dermatol 166:938–947. https://doi.org/10.1111/j.1365-2133.2012.10821.xCrossRefPubMed

27.

Sotoodian B, Lo J, Lin A (2015) Efficacy of topical calcineurin inhibitors in oral lichen planus. J Cutan Med Surg 19:539–545. https://doi.org/10.1177/1203475415591936CrossRefPubMed

28.

Gupta S, Ghosh S, Gupta S (2017) Interventions for the management of oral lichen planus: a review of the conventional and novel therapies. Oral Dis 23:1029–1042. https://doi.org/10.1111/odi.12634CrossRefPubMed

29.

Rad M, Hashemipoor MA, Mojtahedi A, Zarei MR, Chamani G, Kakoei S, Izadi N (2009) Correlation between clinical and histopathologic diagnoses of oral lichen planus based on modified WHO diagnostic criteria. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 107:796–800. https://doi.org/10.1016/j.tripleo.2009.02.020CrossRefPubMed

30.

Pendleton N, Clague JE, Horan MA, Rabbitt PMA, Jones M, Coward R, Lowe C, McInnes L (2004) Concordance of Cornell medical index self-reports to structured clinical assessment for the identification of physical health status. Arch Gerontol Geriatr 38:261–269. https://doi.org/10.1016/j.archger.2003.10.005CrossRefPubMed

31.

Thongprasom K, Luengvisut P, Wongwatanakij A, Boonjatturus C (2003) Clinical evaluation in treatment of oral lichen planus with topical fluocinolone acetonide: a 2-year follow-up. J Oral Pathol Med 32:315–322CrossRef

32.

Scott J, Huskisson EC (1976) Graphic representation of pain. Pain 2:175–184. https://doi.org/10.1016/0304-3959(76)90113-5CrossRef

33.

Hegarty AM, Hodgson TA, Lewsey JD, Porter SR (2002) Fluticasone propionate spray and betamethasone sodium phosphate mouth rinse: a randomized crossover study for the treatment of symptomatic oral lichen planus. J Am Acad Dermatol 47:271–279. https://doi.org/10.1067/mjd.2002.120922CrossRefPubMed

34.

Malhotra AK, Khaitan BK, Sethuraman G, Sharma VK (2008) Betamethasone oral mini-pulse therapy compared with topical triamcinolone acetonide (0.1%) paste in oral lichen planus: a randomized comparative study. J Am Acad Dermatol 58:596–602. https://doi.org/10.1016/j.jaad.2007.11.022CrossRefPubMed

35.

Dissemond J, Schröter S, Franckson T et al (2004) Pimecrolimus in an adhesive ointment as a new treatment option for oral lichen planus [9]. Br J Dermatol 150:782–784CrossRef

36.

Dissemond J (2008) Pimecrolimus in an adhesive ointment is safe and effective in long-term treatment for oral lichen planus. J Eur Acad Dermatol Venereol 22(8):1009–1011CrossRef

37.

Ibrahim SS, Hazzaa HH (2012) Topical pimecrolimus effect on Fas inducing apoptosis in oral lichen planus: a clinical immunohistochemical study. J Oral Pathol Med 41:315–321. https://doi.org/10.1111/j.1600-0714.2011.01099.xCrossRefPubMed

38.

Herold MJ, McPherson KG, Reichardt HM (2006) Glucocorticoids in T cell apoptosis and function. Cell Mol Life Sci 63:60–72CrossRef

39.

Laeijendecker R, Tank B, Dekker SK, Neumann H a M (2006) A comparison of treatment of oral lichen planus with topical tacrolimus and triamcinolone acetonide ointment. Acta Derm Venereol 86:227–229. https://doi.org/10.2340/00015555-0070CrossRefPubMed

40.

Arduino PG, Carbone M, Della Ferrera F, Elia A, Conrotto D, Gambino A, Comba A, Calogiuri PL, Broccoletti R (2014) Pimecrolimus vs. tacrolimus for the topical treatment of unresponsive oral erosive lichen planus: a 8 week randomized double-blind controlled study. J Eur Acad Dermatol Venereol 28:475–482. https://doi.org/10.1111/jdv.12128CrossRefPubMed

41.

Simon D, Vassina E, Yousefi S, Braathen LR, Simon HU (2005) Inflammatory cell numbers and cytokine expression in atopic dermatitis after topical pimecrolimus treatment. Allergy 60:944–951. https://doi.org/10.1111/j.1398-9995.2005.00798.xCrossRefPubMed

42.

Kalthoff FS, Chung J, Musser P, Stuetz a (2003) Pimecrolimus does not affect the differentiation, maturation and function of human monocyte-derived dendritic cells, in contrast to corticosteroids. Clin Exp Immunol 133:350–359. doi: https://doi.org/10.1046/j.1365-2249.2003.02225.x

43.

Luger T, Paul C (2007) Potential new indications of topical calcineurin inhibitors. Dermatology 215:45–54CrossRef

44.

Tudor D, Locke M, Owen-Jones E, Mackenzie IC (2004) Intrinsic patterns of behavior of epithelial stem cells. J Investig Dermatol Symp Proc 9:208–214. https://doi.org/10.1111/j.1087-0024.2004.09310.xCrossRefPubMed

45.

González-Moles MA, Bravo M, Ruiz-Avila I et al (2004) Adhesion molecule CD44 expression in non-tumour epithelium adjacent to tongue cancer. Oral Oncol 40:281–286CrossRef

46.

Clay MR, Tabor M, Owen JH, Carey TE, Bradford CR, Wolf GT, Wicha MS, Prince ME (2010) Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head Neck 32:1195–1201. https://doi.org/10.1002/hed.21315CrossRefPubMedPubMedCentral

47.

Richard V, Pillai MR (2010) The stem cell code in oral epithelial tumorigenesis: “the cancer stem cell shift hypothesis”. Biochim Biophys Acta 1806:146–162. https://doi.org/10.1016/j.bbcan.2010.06.004CrossRefPubMed

48.

González-Moles MA, Scully C, Ruiz-Ávila I, Plaza-Campillo JJ (2013) The cancer stem cell hypothesis applied to oral carcinoma. Oral Oncol 49:738–746. https://doi.org/10.1016/j.oraloncology.2013.04.002CrossRefPubMed

49.

Wang X, Tang G, Sun H (2015) Effect of hypoxia on the proliferation and expressions of hypoxia-inducible factor-1α, vascular endothelial growth factor and matrix metalloproteinase-9 in keratinocytes obtained from oral lichen planus lesions. Zhonghua Kou Qiang Yi Xue Za Zhi 50:89–94PubMed

50.

de Carvalho Fraga CA, Alves LR, Marques-Silva L, de Sousa AA, Jorge ASB, de Jesus SF, Vilela DN, Pinheiro UB, Jones KM, de Paula AMB, Guimarães ALS (2013) High HIF-1α expression genotypes in oral lichen planus. Clin Oral Investig 17:2011–2015. https://doi.org/10.1007/s00784-013-0920-8CrossRefPubMed

51.

Iida H, Suzuki M, Goitsuka R, Ueno H (2012) Hypoxia induces CD133 expression in human lung cancer cells by up-regulation of OCT3/4 and SOX2. Int J Oncol 40:71–79. https://doi.org/10.3892/ijo.2011.1207CrossRefPubMed

52.

Holm M, Kvistgaard H, Dahl C, Andersen HB, Hansen TK, Schiøtz PO, Junker S (2006) Modulation of chemokine gene expression in CD133+ cord blood-derived human mast cells by cyclosporin a and dexamethasone. Scand J Immunol 64:571–579. https://doi.org/10.1111/j.1365-3083.2006.01835.xCrossRefPubMed

53.

Walczak-Drzewiecka A, Ratajewski M, Wagner W, Dastych J (2008) HIF-1alpha is up-regulated in activated mast cells by a process that involves calcineurin and NFAT. J Immunol 181:1665–1672CrossRef

Titel: Topical pimecrolimus versus betamethasone for oral lichen planus: a randomized clinical trial
verfasst von: Ola M. Ezzatt
Iman M. Helmy
Publikationsdatum: 16.06.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Clinical Oral Investigations / Ausgabe 2/2019
Print ISSN: 1432-6981
Elektronische ISSN: 1436-3771
DOI: https://doi.org/10.1007/s00784-018-2519-6

Neu im Fachgebiet Zahnmedizin

19.04.2024 | Vorhofflimmern | Nachrichten

Newsletter bestellen

Springer Medizin

Topical pimecrolimus versus betamethasone for oral lichen planus: a randomized clinical trial

Abstract

Objectives

Material and methods

Results

Conclusion

Clinical relevance

Neu im Fachgebiet Zahnmedizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Invasive Zahnbehandlung: Wann eine Antibiotikaprophylaxe vor infektiöser Endokarditis schützt

Zell-Organisatoren unter Druck: Mechanismen des embryonalen Zahnwachstums aufgedeckt

Die Oralprophylaxe & Kinderzahnheilkunde umbenannt

Newsletter

Springer Medizin

Abstract

Objectives

Material and methods

Results

Conclusion

Clinical relevance

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2019

One-year clinical evaluation of bulk-fill flowable vs. regular nanofilled composite in non-carious cervical lesions

Laterally positioned flap along with acellular dermal matrix graft in the management of maxillary localized recessions

Molecular imaging assessment of periodontitis lesions in an experimental mouse model

Micro-CT evaluation of different final irrigation protocols on the removal of hard-tissue debris from isthmus-containing mesial root of mandibular molars

Influence of pH on osteoclasts treated with zoledronate and alendronate

Immunohistochemical analysis of BRAF V600E mutation in ameloblastomas

Neu im Fachgebiet Zahnmedizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Invasive Zahnbehandlung: Wann eine Antibiotikaprophylaxe vor infektiöser Endokarditis schützt

Zell-Organisatoren unter Druck: Mechanismen des embryonalen Zahnwachstums aufgedeckt

Die Oralprophylaxe & Kinderzahnheilkunde umbenannt

Newsletter